摘要
目的探讨艾尔巴韦/格拉瑞韦(elbasvir/grazoprevir,EBR/GZR)治疗1b型儿童慢性丙型肝炎(chronic hepatitis C,CHC)的疗效和短期安全性。方法收集2019年1月—2022年3月的基因1b型儿童CHC,给予EBR/GZR治疗12周,停药随访12周的生化学指标、病毒学指标等。主要疗效指标为治疗结束后随访12周时患儿获得持续病学应答(sustained virological response,SVR)和治疗期间的不良反应发生的情况。结果5例儿童CHC,男3例,女2年,平均年龄7.68岁。母亲传播2例、祖父传播1例、父亲传播1例、1例不详。EBR/GZR治疗4周、8周、12周和停药12周的SVR分别为60%、100%、100%、100%。丙氨酸氨基转移酶和天冬氨酸氨基转移酶在治疗4周时均恢复正常。不良反应中,1例出现轻微恶心。结论EBR/GZR治疗儿童1b型CHC的疗效和短期安全性较好。
Objective To explore the efficacy and short-term safety of elbasvir/grazoprevir(EBR/GZR)in the treatment of chronic hepatitis C(CHC)genotype 1b in children.Methods The children infected with genotype 1b hepatitis C virus enrolled from January 2019 to March 2022 were given EBR/GZR treatment for 12 weeks,and followed-up for biochemical and virological indicators for 12 weeks after drug withdrawal.The main efficacy indicators were the sustained virological response(SVR)obtained at the end of the treatment and the occurrence of adverse reactions during the treatment.Results There were 5 CHC children,with 3 males and 2 females,and an average of 7.68 years.There were 2 cases of mother transmission,1 of grandfather transmission,1 of father transmission,and 1 was unknown of the transmission route.The SVR of EBR/GZR treatment for 4,8,12 weeks,and 12 weeks after drug withdrawal were 60%,100%,100%and 100%,respectively.In all patients alanine transferase and aspartate transferase returned to normal after 4 weeks of treatment.For the adverse reactions,there was only 1 case with slightly nausea.Conclusion EBR/GZR was effective and safe for the treatment of CHC genotype 1b children.
作者
刘立
李梅
常丽仙
刘春云
李惠敏
方铭
李俊义
LIU Li;LI Mei;CHANG Li-xian;LIU Chun-yun;LI Hui-min;FANG Ming;LI Jun-yi(Yunnan Infectious Diseases Clinical Medical Center,the Third People’s Hospital of Kunming,Kunming 650041,China;Department of Infectious Diseases,Fuyuan County People′s Hospital,Yunnan 655500,China)
出处
《肝脏》
2023年第9期1041-1043,1067,共4页
Chinese Hepatology